✨ Free AI Report
Zai Lab Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Zai Lab Limited
Company Research

Zai Lab Limited: Business Overview, Financials & Competitive Analysis

Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on discovering, developing, and commercializing innovative products that address medic...

Analyst-debate audio for Zai Lab Limited

AskCyborg analysts argue the bull and bear cases for Zai Lab Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Zai Lab is transitioning from a profitable China-focused operator to a globally competitive biopharmaceutical company with late-stage oncology pipeline catalysts positioned for potential first U.S.

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology, Immunology, Neuroscience, Infectious Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Zai Lab Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Zai Lab Limited Overview

Pro stress-test →

Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious diseases. The company operates as a dual-engine model combining a commercially profitable and scaling China business with a global innovation engine.

Strategic Profile

Pro stress-test →

The company's fully integrated cross-border R&D platform enables faster, more capital-efficient development of high-quality assets, as demonstrated by Zoci's rapid advancement from first-in-human studies to global pivotal trials. The China commercial business remains a key source of stability and funding for R&D, while the global oncology and immunology pipeline has reached a scale and maturity with a clear path toward the company's first potential U.S. approval by 2028.

Competitive Landscape

Pro stress-test →

Zai Lab has strategic partnerships with industry giants including Tesaro Inc., NovoCure Ltd., Deciphera Pharmaceuticals, Paratek Bermuda Ltd., argenx SE., Bristol Myers Squibb, Mirati Therapeutics, Amgen Inc., Innoviva Inc., and Karuna Therapeutics. The company competes against multinational biopharmaceutical firms while leveraging its China commercial advantage to fund global R&D.

Industry Context

Zai Lab Limited operates in Biopharmaceutical - Oncology, Immunology, Neuroscience, Infectious Diseases.

Key facts

Founded: 2013 · Headquarters: Shanghai, China · Revenue: $460M · Market cap: $2.17B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Zai Lab Limited.

  • Zoci reached global Phase III quickly; pivotal trials plan for 75% enrollment by year-end with about 30% of patients from China.
  • Expected launch of COBENFY and continued growth of existing product franchises are expected to further strengthen the Company's financial foundation.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Q4 2025 earnings: Full-year revenue grew 15% to $460 million; company withheld 2026 guidance citing VYVGART pricing dynamics and hospital purchasing behavior
  • January 2026Outlined 2026 strategic priorities with Zoci Phase III advancement, multiple novel oncology/immunology assets entering clinic, and expected COBENFY China launch
  • +1 moreTrack every material event for Zai Lab Limited as it happens. Explore monitoring →
Get alerted when Zai Lab Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ZejulaPARP inhibitor for ovarian cancer→OptuneTumor Treating Fields for glioblastoma→VYVGARTAntibody for myasthenia gravis→

Compare Zai Lab Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Zai Lab Limited operates in Biopharmaceutical - Oncology, Immunology, Neuroscience, Infectious Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology, Immunology, Neuroscience, Infectious Diseases research →
NEW · MCP server

Ask your AI assistant about Zai Lab Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Zai Lab Limited and its top competitor on Cyborg Score”
“What did Zai Lab Limited do this quarter?”
“Is Zai Lab Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Zai Lab Limited do?+
Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on discovering, developing, and commercializing innovative products that address medic...
What is Zai Lab Limited's Cyborg Score?+
Zai Lab Limited has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Zai Lab Limited's main competitors?+
Named competitors include Zejula, Optune, VYVGART. The full competitive landscape is in the AskCyborg report.
How can I get the full Zai Lab Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Zai Lab Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Zai Lab Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Syndax Pharmaceuticals, Inc.7Puma Biotechnology, Inc.7Zai Lab Limited6Genenta Science4BioAtla, Inc.4Mersana Therapeutics, Inc.4Propanc Biopharma, Inc.3MacroGenics, Inc.